Phase 2
N=286
Mindfulness Based Relapse Prevention: Efficacy and Mechanisms
Substance Use Disorders
Bottom Line
View on ClinicalTrials.gov: NCT01159535 ↗Enrolled (actual)
286
Serious AEs
0.0%
Results posted
Aug 2016
Primary outcome: Primary: Mean Number of Alcohol and Drug Use Days Out of Past 30 — 1.44; 3.89; 4.65; 3.06 number of days out of past 30
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Mindfulness Based Relapse Prevention (Behavioral); Relapse Prevention (Behavioral); Treatment as Usual (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Washington
- Primary completion
- Jul 2012
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Number of Alcohol and Drug Use Days Out of Past 30 |
1.44; 3.89; 4.65; 3.06; 6.09; 4.63 | — |
Summary
The broad, long-term objective of the proposed randomized clinical trial is to evaluate the efficacy, moderators and mechanisms of change of two cognitive-behavioral aftercare treatments for alcohol and other drug (AOD) use disorders in preventing AOD relapse compared to treatment as usual (TAU) offered in the community. The two cognitive-behavioral aftercare treatments are relapse prevention (RP) and Mindfulness-Based Relapse Prevention (MBRP), which integrates mindfulness meditation and RP aftercare components.
Eligibility Criteria
Inclusion Criteria
- completion or scheduled completion (i.e., within 2 weeks) of Inpatient or Intensive Outpatient treatment
- fluency in English
- enrollment in a substance abuse aftercare program
- medical clearance by referring provider
- willingness to accept random assignment to treatment condition
Exclusion Criteria
- already participated in the pilot MBRP trial conducted by this research team
- participation in the comorbid disorders or relapse prevention groups offered at partner agency
- comorbid psychosis (including schizophrenia, schizoaffective or other schizophreniform disorder)and/or dementia, acute suicidality/intent to harm others, severe cognitive impairment, and high risk of withdrawal or medical complications stemming from relapse which would require a higher level of care.
Data sourced from ClinicalTrials.gov (NCT01159535). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.